PET/CT IN THE DIAGNOSIS OF LYMPHOMAS

 

Alekseev S.A., Troyan V.N., Rukavicyn O.A., Trefilov A.A.

 

N.N. Burdenko Main Military Clinical Hospital, Ministry of Defense of the Russian Federation. Moscow, Russia.

PET/CT with FDG is currently an integral part of the diagnosis and treatment in lymphomas. Due to its accuracy compared to CT, PET/CT is the method of choice for determining the stage and evaluating the treatment response in most lymphomas. In addition, PET/CT results can be used to predict the course of the disease or potential escalation or de-escalation of treatment in the early stages of therapy.

Much attention is paid to the radiomics of lymphoproliferative blood diseases. Indicators such as the standardized value of radiopharmaceutical uptake, the metabolic volume of the tumor and total glycolysis in the lesions are being studied as reproducible and potentially more accurate predictive factors of treatment response and prognosis.

Despite the progress made in standardizing of PET/CT results interpretation, problems remain,

 

especially with regard to limited predictive value, which underscores the need to find and implement more specific radiopharmaceuticals.

The review examines the most relevant areas of PET/CT application in Hodgkin's lymphoma and non-Hodgkin's lymphomas, as well as the strengths and weaknesses of the method.

 

Keywords: positron emission tomography, computed tomography, lymphoma, fluorodeoxyglucose, radiopharmaceutical, non-Hodgkin's lymphoma, Hodgkin's lymphoma.

 

Corresponding author: Alekseev S.A., e-mail: Этот e-mail адрес защищен от спам-ботов, для его просмотра у Вас должен быть включен Javascript

 

For citation: Alekseev S.A., Troyan V.N., Rukavicyn O.A., Trefilov A.A. PЕТ/CT in the diagnosis of lymphomas. REJR 2025; 15(2):120-131. DOI: 10.21569/2222-7415-2025-15-2-120-131.

Received:        16.01.25                 Accepted:       03.04.25